Ex-post analysis of medicines subject to Managed-Entry-Agreements (MEAs) – a feasible approach for monitoring and price analyses.

The EURIPID collaboration is currently funded by an annual contribution fee of the participants and – for defined tasks and deliverables – a grant of the EU.

This website is part of the project ’826652 Euripid’ which is co-funded by the European Union’s Health Programme (2014-2020).

The content of this website represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.

Ex-post analysis of medicines subject to Managed-Entry-Agreements (MEAs) – a feasible approach for monitoring and price analyses.

Collaborating Across Europe to Ensure Fair, Accessible, and Sustainable Healthcare

© Copyright – EURIPID